ImmunoGen, Inc. Announces Conference Call at 8:00 am ET March 30, 2012 to Discuss Today's Favorable Announcements about Trastuzumab Emtansine (T-DM1) and about IMGN901
WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops
targeted anticancer products, today announced that it will host a
conference call at 8:00 am ET on Friday, March 30, 2012 to discuss the
two releases issued by the Company earlier today:
The announcement of positive results in the trastuzumab emtansine
(T-DM1) EMILIA Phase III trial; and
The announcement of initiation of Phase II evaluation of IMGN901.
To access the live call by phone, dial 913-312-0982. Passcode is
8250254. The call also may be accessed through the Investor Information
section of the Company's website, www.immunogen.com.
Following the live webcast, a replay of the call will be available at
the same location through April 6, 2012.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the
Company's expertise in tumor biology, monoclonal antibodies, potent
cancer-cell killing agents and engineered linkers. The Company's
Targeted Antibody Payload (TAP) technology uses monoclonal antibodies to
deliver one of ImmunoGen's proprietary cancer-cell killing agents
specifically to tumor cells. There are now numerous TAP compounds in
clinical development with a wealth of clinical data reported.
ImmunoGen's collaborative partners include Amgen, Bayer HealthCare,
Biotest, Lilly, Novartis, Roche, and Sanofi. The most advanced compound
using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in
Phase III testing through the Company's collaboration with Genentech, a
member of the Roche Group. More information about ImmunoGen can be found
Carol Hausner, 781-895-0600
Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153
Source: ImmunoGen, Inc.
News Provided by Acquire Media
Close window | Back to top